Targeted measles virus vector displaying echistatin infects endothelial cells via αvβ3 and leads to tumor regression

Louay K. Hallak, Jaime R Merchan, Chris M. Storgard, Joseph C. Loftus, Stephen J. Russell

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Targeting tumor-associated vascular endothelium by replication-competent viral vectors is a promising strategy for cancer gene therapy. Here we describe the development of a viral vector based on the Edmonston vaccine strain of measles virus targeted to integrin αvβ3, which is expressed abundantly on activated but not quiescent vascular endothelium. We displayed a disintegrin, M28L echistatin that binds with a high affinity to integrin αvβ3 on the COOH terminus of the viral attachment (H) protein and rescued the replication-competent recombinant virus by reverse genetics. The new targeted virus was named measles virus echistatin vector (MV-ERV). Its native binding to CD46 was purpose-fully retained to allow virus infection of tumor cells expressing this receptor. MV-ERV correctly displayed echistatin on the outer surface of its envelope and produced interesting ring formation phenomena due to cell detachment upon infection of susceptible Vero cells in vitro. MV-ERV grew to 106 plaque-forming units/mL, slightly lower than the parental Edmonston strain of measles virus (MV-Edm), but it selectively infected Chinese hamster ovary cells expressing integrin αvβ3. It also selectively infected both bovine and human endothelial cells on matrigels and unlike MV-Edm, MV-ERV infected newly formed blood vessels in chorioallantoic membrane assays. In animal models, MV-ERV but not the control MV-Edm caused the regression of s.c. xenografts of resistant multiple myeloma tumors (MM1) in severe combined immunodeficient mice. The tumors were either completely eradicated or their growth was significantly retarded. The specificity, potency, and feasibility of MV-ERV infection clearly show the potential use of MV-ERV in gene therapy for targeting tumor-associated vasculature for the treatment of solid tumors.

Original languageEnglish
Pages (from-to)5292-5300
Number of pages9
JournalCancer Research
Volume65
Issue number12
DOIs
StatePublished - Jun 15 2005
Externally publishedYes

Fingerprint

Endogenous Retroviruses
Measles virus
Endothelial Cells
Neoplasms
Integrins
Vascular Endothelium
Genetic Therapy
Tumor Virus Infections
Viruses
Disintegrins
Chorioallantoic Membrane
Reverse Genetics
Vero Cells
SCID Mice
Gene Targeting
Neoplasm Genes
Cricetulus
Infection
echistatin
Multiple Myeloma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Targeted measles virus vector displaying echistatin infects endothelial cells via αvβ3 and leads to tumor regression. / Hallak, Louay K.; Merchan, Jaime R; Storgard, Chris M.; Loftus, Joseph C.; Russell, Stephen J.

In: Cancer Research, Vol. 65, No. 12, 15.06.2005, p. 5292-5300.

Research output: Contribution to journalArticle

Hallak, Louay K. ; Merchan, Jaime R ; Storgard, Chris M. ; Loftus, Joseph C. ; Russell, Stephen J. / Targeted measles virus vector displaying echistatin infects endothelial cells via αvβ3 and leads to tumor regression. In: Cancer Research. 2005 ; Vol. 65, No. 12. pp. 5292-5300.
@article{1022e475c54c4c2b830135649635f06a,
title = "Targeted measles virus vector displaying echistatin infects endothelial cells via αvβ3 and leads to tumor regression",
abstract = "Targeting tumor-associated vascular endothelium by replication-competent viral vectors is a promising strategy for cancer gene therapy. Here we describe the development of a viral vector based on the Edmonston vaccine strain of measles virus targeted to integrin αvβ3, which is expressed abundantly on activated but not quiescent vascular endothelium. We displayed a disintegrin, M28L echistatin that binds with a high affinity to integrin αvβ3 on the COOH terminus of the viral attachment (H) protein and rescued the replication-competent recombinant virus by reverse genetics. The new targeted virus was named measles virus echistatin vector (MV-ERV). Its native binding to CD46 was purpose-fully retained to allow virus infection of tumor cells expressing this receptor. MV-ERV correctly displayed echistatin on the outer surface of its envelope and produced interesting ring formation phenomena due to cell detachment upon infection of susceptible Vero cells in vitro. MV-ERV grew to 106 plaque-forming units/mL, slightly lower than the parental Edmonston strain of measles virus (MV-Edm), but it selectively infected Chinese hamster ovary cells expressing integrin αvβ3. It also selectively infected both bovine and human endothelial cells on matrigels and unlike MV-Edm, MV-ERV infected newly formed blood vessels in chorioallantoic membrane assays. In animal models, MV-ERV but not the control MV-Edm caused the regression of s.c. xenografts of resistant multiple myeloma tumors (MM1) in severe combined immunodeficient mice. The tumors were either completely eradicated or their growth was significantly retarded. The specificity, potency, and feasibility of MV-ERV infection clearly show the potential use of MV-ERV in gene therapy for targeting tumor-associated vasculature for the treatment of solid tumors.",
author = "Hallak, {Louay K.} and Merchan, {Jaime R} and Storgard, {Chris M.} and Loftus, {Joseph C.} and Russell, {Stephen J.}",
year = "2005",
month = "6",
day = "15",
doi = "10.1158/0008-5472.CAN-04-2879",
language = "English",
volume = "65",
pages = "5292--5300",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Targeted measles virus vector displaying echistatin infects endothelial cells via αvβ3 and leads to tumor regression

AU - Hallak, Louay K.

AU - Merchan, Jaime R

AU - Storgard, Chris M.

AU - Loftus, Joseph C.

AU - Russell, Stephen J.

PY - 2005/6/15

Y1 - 2005/6/15

N2 - Targeting tumor-associated vascular endothelium by replication-competent viral vectors is a promising strategy for cancer gene therapy. Here we describe the development of a viral vector based on the Edmonston vaccine strain of measles virus targeted to integrin αvβ3, which is expressed abundantly on activated but not quiescent vascular endothelium. We displayed a disintegrin, M28L echistatin that binds with a high affinity to integrin αvβ3 on the COOH terminus of the viral attachment (H) protein and rescued the replication-competent recombinant virus by reverse genetics. The new targeted virus was named measles virus echistatin vector (MV-ERV). Its native binding to CD46 was purpose-fully retained to allow virus infection of tumor cells expressing this receptor. MV-ERV correctly displayed echistatin on the outer surface of its envelope and produced interesting ring formation phenomena due to cell detachment upon infection of susceptible Vero cells in vitro. MV-ERV grew to 106 plaque-forming units/mL, slightly lower than the parental Edmonston strain of measles virus (MV-Edm), but it selectively infected Chinese hamster ovary cells expressing integrin αvβ3. It also selectively infected both bovine and human endothelial cells on matrigels and unlike MV-Edm, MV-ERV infected newly formed blood vessels in chorioallantoic membrane assays. In animal models, MV-ERV but not the control MV-Edm caused the regression of s.c. xenografts of resistant multiple myeloma tumors (MM1) in severe combined immunodeficient mice. The tumors were either completely eradicated or their growth was significantly retarded. The specificity, potency, and feasibility of MV-ERV infection clearly show the potential use of MV-ERV in gene therapy for targeting tumor-associated vasculature for the treatment of solid tumors.

AB - Targeting tumor-associated vascular endothelium by replication-competent viral vectors is a promising strategy for cancer gene therapy. Here we describe the development of a viral vector based on the Edmonston vaccine strain of measles virus targeted to integrin αvβ3, which is expressed abundantly on activated but not quiescent vascular endothelium. We displayed a disintegrin, M28L echistatin that binds with a high affinity to integrin αvβ3 on the COOH terminus of the viral attachment (H) protein and rescued the replication-competent recombinant virus by reverse genetics. The new targeted virus was named measles virus echistatin vector (MV-ERV). Its native binding to CD46 was purpose-fully retained to allow virus infection of tumor cells expressing this receptor. MV-ERV correctly displayed echistatin on the outer surface of its envelope and produced interesting ring formation phenomena due to cell detachment upon infection of susceptible Vero cells in vitro. MV-ERV grew to 106 plaque-forming units/mL, slightly lower than the parental Edmonston strain of measles virus (MV-Edm), but it selectively infected Chinese hamster ovary cells expressing integrin αvβ3. It also selectively infected both bovine and human endothelial cells on matrigels and unlike MV-Edm, MV-ERV infected newly formed blood vessels in chorioallantoic membrane assays. In animal models, MV-ERV but not the control MV-Edm caused the regression of s.c. xenografts of resistant multiple myeloma tumors (MM1) in severe combined immunodeficient mice. The tumors were either completely eradicated or their growth was significantly retarded. The specificity, potency, and feasibility of MV-ERV infection clearly show the potential use of MV-ERV in gene therapy for targeting tumor-associated vasculature for the treatment of solid tumors.

UR - http://www.scopus.com/inward/record.url?scp=20444462768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20444462768&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-04-2879

DO - 10.1158/0008-5472.CAN-04-2879

M3 - Article

VL - 65

SP - 5292

EP - 5300

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 12

ER -